Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 459

1.

Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy.

MacLeod AK, Lin, Huang JT, McLaughlin LA, Henderson CJ, Wolf CR.

Clin Cancer Res. 2018 May 1;24(9):2138-2147. doi: 10.1158/1078-0432.CCR-17-3555. Epub 2018 Feb 6.

PMID:
29437786
2.

Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.

Sheth H, Northwood E, Ulrich CM, Scherer D, Elliott F, Barrett JH, Forman D, Wolf CR, Smith G, Jackson MS, Santibanez-Koref M, Haile R, Casey G, Jenkins M, Win AK, Hopper JL, Marchand LL, Lindor NM, Thibodeau SN, Potter JD, Burn J, Bishop DT.

PLoS One. 2018 Feb 9;13(2):e0192223. doi: 10.1371/journal.pone.0192223. eCollection 2018.

3.

Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice.

Reed L, Mrizova I, Barta F, Indra R, Moserova M, Kopka K, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM.

Arch Toxicol. 2018 Apr;92(4):1625-1638. doi: 10.1007/s00204-018-2162-7. Epub 2018 Jan 24.

4.

Measuring in vivo responses to endogenous and exogenous oxidative stress using a novel haem oxygenase 1 reporter mouse.

McMahon M, Ding S, Acosta-Jimenez LP, Frangova TG, Henderson CJ, Wolf CR.

J Physiol. 2018 Jan 1;596(1):105-127. doi: 10.1113/JP274915. Epub 2017 Nov 23.

5.

Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites.

Lin, Kostov R, Huang JT, Henderson CJ, Wolf CR.

J Pharmacol Exp Ther. 2017 Oct;363(1):12-19. doi: 10.1124/jpet.117.243246.

6.

Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.

MacLeod AK, Acosta-Jimenez L, Coates PJ, McMahon M, Carey FA, Honda T, Hayes JD, Henderson CJ, Wolf CR.

Br J Cancer. 2017 Aug 22;117(5):e1. doi: 10.1038/bjc.2017.80. Epub 2017 Mar 21.

7.

Feedback control of AHR signalling regulates intestinal immunity.

Schiering C, Wincent E, Metidji A, Iseppon A, Li Y, Potocnik AJ, Omenetti S, Henderson CJ, Wolf CR, Nebert DW, Stockinger B.

Nature. 2017 Feb 9;542(7640):242-245. doi: 10.1038/nature21080. Epub 2017 Feb 1.

8.

Aryl hydrocarbon receptor is required for optimal B-cell proliferation.

Villa M, Gialitakis M, Tolaini M, Ahlfors H, Henderson CJ, Wolf CR, Brink R, Stockinger B.

EMBO J. 2017 Jan 4;36(1):116-128. doi: 10.15252/embj.201695027. Epub 2016 Nov 14.

9.

Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.

MacLeod AK, Acosta-Jimenez L, Coates PJ, McMahon M, Carey FA, Honda T, Henderson CJ, Wolf CR.

Br J Cancer. 2016 Dec 6;115(12):1530-1539. doi: 10.1038/bjc.2016.363. Epub 2016 Nov 8. Erratum in: Br J Cancer. 2017 Aug 22;117(5):e1.

10.

Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.

MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR.

Drug Metab Dispos. 2017 Jan;45(1):17-22. Epub 2016 Oct 18.

11.

Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans.

Takahashi S, Fukami T, Masuo Y, Brocker CN, Xie C, Krausz KW, Wolf CR, Henderson CJ, Gonzalez FJ.

J Lipid Res. 2016 Dec;57(12):2130-2137. Epub 2016 Sep 16.

12.

Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New p21 Reporter Mouse.

McMahon M, Frangova TG, Henderson CJ, Wolf CR.

Mol Cancer Res. 2016 Dec;14(12):1195-1203. Epub 2016 Sep 7.

13.

Patterns of bacterial biodiversity in the glacial meltwater streams of the McMurdo Dry Valleys, Antarctica.

Van Horn DJ, Wolf CR, Colman DR, Jiang X, Kohler TJ, McKnight DM, Stanish LF, Yazzie T, Takacs-Vesbach CD.

FEMS Microbiol Ecol. 2016 Oct;92(10). pii: fiw148. doi: 10.1093/femsec/fiw148. Epub 2016 Aug 5.

14.

Attenuation of lung fibrosis in mice with a clinically relevant inhibitor of glutathione-S-transferase π.

McMillan DH, van der Velden JL, Lahue KG, Qian X, Schneider RW, Iberg MS, Nolin JD, Abdalla S, Casey DT, Tew KD, Townsend DM, Henderson CJ, Wolf CR, Butnor KJ, Taatjes DJ, Budd RC, Irvin CG, van der Vliet A, Flemer S, Anathy V, Janssen-Heininger YM.

JCI Insight. 2016 Jun 2;1(8). pii: e85717.

15.

Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer.

Thomson JP, Ottaviano R, Unterberger EB, Lempiäinen H, Muller A, Terranova R, Illingworth RS, Webb S, Kerr AR, Lyall MJ, Drake AJ, Wolf CR, Moggs JG, Schwarz M, Meehan RR.

Cancer Res. 2016 May 15;76(10):3097-108. doi: 10.1158/0008-5472.CAN-15-1910. Epub 2016 Apr 6.

16.

The Role of Protein-Protein and Protein-Membrane Interactions on P450 Function.

Scott EE, Wolf CR, Otyepka M, Humphreys SC, Reed JR, Henderson CJ, McLaughlin LA, Paloncýová M, Navrátilová V, Berka K, Anzenbacher P, Dahal UP, Barnaba C, Brozik JA, Jones JP, Estrada DF, Laurence JS, Park JW, Backes WL.

Drug Metab Dispos. 2016 Apr;44(4):576-90. doi: 10.1124/dmd.115.068569. Epub 2016 Feb 5. Review.

17.

Model Systems for Understanding Mechanisms of Nongenotoxic Carcinogenesis: Response.

Braeuning A, Henderson CJ, Wolf CR, Schwarz M.

Toxicol Sci. 2015 Oct;147(2):299-300. No abstract available.

PMID:
26668886
18.

Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models.

MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR.

Cancer Res. 2015 Nov 1;75(21):4573-81. doi: 10.1158/0008-5472.CAN-15-1454. Epub 2015 Sep 11.

19.

Altered protein S-glutathionylation identifies a potential mechanism of resistance to acetaminophen-induced hepatotoxicity.

McGarry DJ, Chakravarty P, Wolf CR, Henderson CJ.

J Pharmacol Exp Ther. 2015 Nov;355(2):137-44. doi: 10.1124/jpet.115.227389. Epub 2015 Aug 26.

20.

Development of methodology for identification the nature of the polyphenolic extracts by FTIR associated with multivariate analysis.

Grasel Fdos S, Ferrão MF, Wolf CR.

Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 15;153:94-101. doi: 10.1016/j.saa.2015.08.020. Epub 2015 Aug 14.

PMID:
26296253
21.

Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model.

Scheer N, Kapelyukh Y, Rode A, Oswald S, Busch D, McLaughlin LA, Lin D, Henderson CJ, Wolf CR.

Drug Metab Dispos. 2015 Nov;43(11):1679-90. doi: 10.1124/dmd.115.065656. Epub 2015 Aug 11.

22.

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.

Amankwatia EB, Chakravarty P, Carey FA, Weidlich S, Steele RJ, Munro AJ, Wolf CR, Smith G.

Br J Cancer. 2015 Apr 28;112(9):1480-90. doi: 10.1038/bjc.2015.125.

23.

Proteome-wide identification and quantification of S-glutathionylation targets in mouse liver.

McGarry DJ, Chen W, Chakravarty P, Lamont DL, Wolf CR, Henderson CJ.

Biochem J. 2015 Jul 1;469(1):25-32. doi: 10.1042/BJ20141256. Epub 2015 Apr 20.

PMID:
25891661
24.

Evidence that the capacity of nongenotoxic carcinogens to induce oxidative stress is subject to marked variability.

Henderson CJ, Cameron AR, Chatham L, Stanley LA, Wolf CR.

Toxicol Sci. 2015 May;145(1):138-48. doi: 10.1093/toxsci/kfv039. Epub 2015 Feb 17.

25.

Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.

Henderson CJ, McLaughlin LA, Scheer N, Stanley LA, Wolf CR.

Mol Pharmacol. 2015 Apr;87(4):733-9. doi: 10.1124/mol.114.097394. Epub 2015 Feb 5.

26.

An enhanced in vivo stable isotope labeling by amino acids in cell culture (SILAC) model for quantification of drug metabolism enzymes.

MacLeod AK, Fallon PG, Sharp S, Henderson CJ, Wolf CR, Huang JT.

Mol Cell Proteomics. 2015 Mar;14(3):750-60. doi: 10.1074/mcp.M114.043661. Epub 2015 Jan 5.

27.

HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents.

McMahon M, Campbell KH, MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR.

PLoS One. 2014 Nov 26;9(11):e114055. doi: 10.1371/journal.pone.0114055. eCollection 2014.

28.

Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability.

Henderson CJ, McLaughlin LA, Osuna-Cabello M, Taylor M, Gilbert I, McLaren AW, Wolf CR.

Biochem J. 2015 Feb 1;465(3):479-88. doi: 10.1042/BJ20140582.

PMID:
25377919
29.

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

Sawers L, Ferguson MJ, Ihrig BR, Young HC, Chakravarty P, Wolf CR, Smith G.

Br J Cancer. 2014 Sep 9;111(6):1150-8. doi: 10.1038/bjc.2014.386. Epub 2014 Jul 10.

30.

In vivo regulation of human glutathione transferase GSTP by chemopreventive agents.

Henderson CJ, McLaren AW, Wolf CR.

Cancer Res. 2014 Aug 15;74(16):4378-87. doi: 10.1158/0008-5472.CAN-14-0792. Epub 2014 Jun 16.

31.

Phenobarbital-mediated tumor promotion in transgenic mice with humanized CAR and PXR.

Braeuning A, Gavrilov A, Brown S, Wolf CR, Henderson CJ, Schwarz M.

Toxicol Sci. 2014 Aug 1;140(2):259-70. doi: 10.1093/toxsci/kfu099. Epub 2014 May 25.

PMID:
24863967
32.

Phenobarbital induces cell cycle transcriptional responses in mouse liver humanized for constitutive androstane and pregnane x receptors.

Luisier R, Lempiäinen H, Scherbichler N, Braeuning A, Geissler M, Dubost V, Müller A, Scheer N, Chibout SD, Hara H, Picard F, Theil D, Couttet P, Vitobello A, Grenet O, Grasl-Kraupp B, Ellinger-Ziegelbauer H, Thomson JP, Meehan RR, Elcombe CR, Henderson CJ, Wolf CR, Schwarz M, Moulin P, Terranova R, Moggs JG.

Toxicol Sci. 2014 Jun;139(2):501-11. doi: 10.1093/toxsci/kfu038. Epub 2014 Apr 1.

PMID:
24690595
33.

Deletion of 30 murine cytochrome p450 genes results in viable mice with compromised drug metabolism.

Scheer N, McLaughlin LA, Rode A, Macleod AK, Henderson CJ, Wolf CR.

Drug Metab Dispos. 2014 Jun;42(6):1022-30. doi: 10.1124/dmd.114.057885. Epub 2014 Mar 26.

34.

Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions.

Stiborová M, Moserová M, Černá V, Indra R, Dračínský M, Šulc M, Henderson CJ, Wolf CR, Schmeiser HH, Phillips DH, Frei E, Arlt VM.

Toxicology. 2014 Apr 6;318:1-12. doi: 10.1016/j.tox.2014.02.002. Epub 2014 Feb 14.

PMID:
24530354
35.

A targeted in vivo SILAC approach for quantification of drug metabolism enzymes: regulation by the constitutive androstane receptor.

Macleod AK, Zang T, Riches Z, Henderson CJ, Wolf CR, Huang JT.

J Proteome Res. 2014 Feb 7;13(2):866-74. doi: 10.1021/pr400897t. Epub 2013 Dec 12.

36.

A role for cytochrome b5 in the In vivo disposition of anticancer and cytochrome P450 probe drugs in mice.

Henderson CJ, McLaughlin LA, Finn RD, Ronseaux S, Kapelyukh Y, Wolf CR.

Drug Metab Dispos. 2014 Jan;42(1):70-7. doi: 10.1124/dmd.113.055277. Epub 2013 Oct 10.

37.

Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.

Deeni YY, Ibbotson SH, Woods JA, Wolf CR, Smith G.

PLoS One. 2013 Sep 23;8(9):e75494. doi: 10.1371/journal.pone.0075494. eCollection 2013.

38.

Epigenetic profiles as defined signatures of xenobiotic exposure.

Thomson JP, Moggs JG, Wolf CR, Meehan RR.

Mutat Res Genet Toxicol Environ Mutagen. 2014 Apr;764-765:3-9. doi: 10.1016/j.mrgentox.2013.08.007. Epub 2013 Aug 31. Review.

PMID:
24001620
39.

Generation and utility of genetically humanized mouse models.

Scheer N, Snaith M, Wolf CR, Seibler J.

Drug Discov Today. 2013 Dec;18(23-24):1200-11. doi: 10.1016/j.drudis.2013.07.007. Epub 2013 Jul 18. Review.

PMID:
23872278
40.

Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications.

Scheer N, Wolf CR.

Xenobiotica. 2014 Jan;44(2):96-108. doi: 10.3109/00498254.2013.815831. Epub 2013 Jul 11. Review.

PMID:
23845026
41.

The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells.

Plitzko B, Ott G, Reichmann D, Henderson CJ, Wolf CR, Mendel R, Bittner F, Clement B, Havemeyer A.

J Biol Chem. 2013 Jul 12;288(28):20228-37. doi: 10.1074/jbc.M113.474916. Epub 2013 May 23.

42.

Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.

Henderson CJ, McLaughlin LA, Wolf CR.

Mol Pharmacol. 2013 Jun;83(6):1209-17. doi: 10.1124/mol.112.084616. Epub 2013 Mar 25.

43.

Simultaneous non-negative matrix factorization for multiple large scale gene expression datasets in toxicology.

Lee CM, Mudaliar MA, Haggart DR, Wolf CR, Miele G, Vass JK, Higham DJ, Crowther D.

PLoS One. 2012;7(12):e48238. doi: 10.1371/journal.pone.0048238. Epub 2012 Dec 14.

44.

Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice.

Carvalho AN, Marques C, Rodrigues E, Henderson CJ, Wolf CR, Pereira P, Gama MJ.

Mol Neurobiol. 2013 Apr;47(2):662-72. doi: 10.1007/s12035-012-8368-4. Epub 2012 Nov 6.

PMID:
23129554
45.

NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.

Riddick DS, Ding X, Wolf CR, Porter TD, Pandey AV, Zhang QY, Gu J, Finn RD, Ronseaux S, McLaughlin LA, Henderson CJ, Zou L, Flück CE.

Drug Metab Dispos. 2013 Jan;41(1):12-23. doi: 10.1124/dmd.112.048991. Epub 2012 Oct 19.

46.

Water quality assessment using the AREc32 reporter gene assay indicative of the oxidative stress response pathway.

Escher BI, Dutt M, Maylin E, Tang JY, Toze S, Wolf CR, Lang M.

J Environ Monit. 2012 Nov;14(11):2877-85. doi: 10.1039/c2em30506b.

PMID:
23032559
47.

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

Smith G, Ng MT, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, Wolf CR.

Br J Cancer. 2012 Oct 9;107(8):1327-36. doi: 10.1038/bjc.2012.410. Epub 2012 Sep 18.

48.

Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines.

Scheer N, Kapelyukh Y, Chatham L, Rode A, Buechel S, Wolf CR.

Mol Pharmacol. 2012 Dec;82(6):1022-9. doi: 10.1124/mol.112.080036. Epub 2012 Aug 23.

49.

Generation and characterization of a novel multidrug resistance protein 2 humanized mouse line.

Scheer N, Balimane P, Hayward MD, Buechel S, Kauselmann G, Wolf CR.

Drug Metab Dispos. 2012 Nov;40(11):2212-8. doi: 10.1124/dmd.112.047605. Epub 2012 Aug 23.

50.

Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson's disease.

Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson CJ, Wolf CR, Rodrigues CM, Gama MJ.

Mol Neurobiol. 2012 Oct;46(2):475-86. doi: 10.1007/s12035-012-8295-4. Epub 2012 Jul 8.

PMID:
22773138

Supplemental Content

Loading ...
Support Center